Viking Pharmaceutical Trials Inc. — research payments reported

By program year

2 rows

Year	Kind	Amount	Payments
2024	Research	$105,211	11
2023	Research	$61,461	11

Breakdown

Who paid Research payments · program years 2023–2024

Supernus Pharmaceuticals, Inc. $105,211 11 payments
Sumitomo Pharma America, Inc. $61,461 11 payments

Studies the money was for Research payments · program years 2023–2024

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression $105,211 11 payments
A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder $61,461 11 payments

What the money was spent on Research payments · program years 2023–2024

Patient care $105,211 11 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.